599 Results

People

  1. Riely
    Riely
  2. Kris
    Kris
  3. Ladanyi
    Ladanyi
  4. Yu
    Yu
  5. Arcila
    Arcila
  6. Rudin
    Rudin
  7. Rekhtman
    Rekhtman
  8. Drilon
    Drilon
  9. Pao
    Pao
  10. Travis
    Travis

Groups

  1. Department of Medicine (599)
  2. Solid Tumor Oncology Division (599)
  3. Thoracic Oncology (599)
  4. Department of Pathology and Laboratory Medicine (260)
  5. GSK Faculty (244)
  6. Human Oncology and Pathogenesis Program (219)
  7. Tow Center for Developmental Oncology (TCDO) (190)
  8. Epidemiology and Biostatistics (131)
  9. Biostatistics Service (121)
  10. Weinberg Fellows (120)
  1. "Gregory Riely"
Formats
  1. Journal Article (291)
  2. Meeting Abstract (264)
  3. Book Section (16)
  4. Guidelines (14)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Book Whole (1)
  9. Correspondence (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (599)
  2. Solid Tumor Oncology Division (599)
  3. Thoracic Oncology (599)
  4. Department of Pathology and Laboratory Medicine (260)
  5. GSK Faculty (244)
  6. Human Oncology and Pathogenesis Program (219)

More Groups

People
  1. Gregory Riely (599)
  2. Mark Kris (220)
  3. Marc Ladanyi (187)
  4. Helena Yu (107)
  5. Maria Arcila (85)
  6. Vincent Miller (79)

More People

Years
  1. 2025 (3)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (156)
  2. Journal of Thoracic Oncology (112)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (31)
  5. Journal of the National Comprehensive Cancer Network (25)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (173)
  2. Elsevier Inc. (136)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (38)
  5. Harborside Press (25)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (599)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma or thymic carcinoma
    Journal Article

    Marks, J. A.; Ahn, J.; Reuss, J. E.; Barbie, D.; Altan, M.; Gutierrez, M. E.; Garassino, M. C.; Riely, G. J.; Wakelee, H.; Liu, S. V.; more...
    Clinical Lung Cancer (2025)

    Fulltext@MSK | Save
  • Can we find a place for trophoblast cell surface antigen 2-targeted antibody-drug conjugates in lung cancer?
    Editorial

    Cooper, A. J.; Riely, G. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Brief report: Clinical characteristics and outcomes of patients with thoracic SMARCA4-deficient undifferentiated tumors
    Journal Article

    Cooper, A. J.; Arfe, A.; Ricciuti, B.; Gagné, A.; Sholl, L. M.; Di Federico, A.; Awad, M. M.; Aldea, M.; Ghigna, M. R.; Grecea, M.; more...
    JTO Clinical and Research Reports (2025)

    Fulltext@MSK | Save
  • Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) ≥50%: MK-1084-004
    Meeting Abstract

    Cobb, P. W.; Hochmair, M.; Schuler, M. H. H.; Riely, G. J.; Rojas, C. I.; Kim, S. J.; Chen, X.; Lara-Guerra, H.; Felip, E.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Real-world experience with circulating tumor DNA in cerebrospinal fluid in patients with central nervous system tumors
    Meeting Abstract

    Hickman, R.; Miller, A. M.; Holle, B. M.; Jee, J.; Liu, S. Y.; Ross, D.; Yu, H.; Riely, G. J.; Ombres, C.; Gerwitz, A.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma and thymic carcinoma
    Meeting Abstract

    Marks, J. A.; Agarwal, S.; Ahn, J.; Reuss, J. E.; Altan, M.; Nabel, C.; Gutierrez, M. E.; Garassino, M. C.; Riely, G. J.; Wakelee, H.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Automated real-world data integration improves cancer outcome prediction
    Journal Article

    Jee, J.; Fong, C.; Pichotta, K.; Tran, T. N.; Luthra, A.; Waters, M.; Fu, C.; Altoe, M.; Liu, S. Y.; Maron, S. B.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
    Journal Article

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Iwama, E.; Inoue, T.; Rodríguez-Cid, J.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Annotated test-retest dataset of lung cancer CT scan images reconstructed at multiple imaging parameters
    Journal Article

    Zhao, B.; Dercle, L.; Yang, H.; Riely, G. J.; Kris, M. G.; Schwartz, L. H.
    Scientific Data (2024)

    Fulltext@MSK | Save